US-based Mylan NV (NASDAQ: MYL) has restarted production of hydroxychloroquine sulfate tablets at its West Virginia manufacturing facility in the US intended for treating COVID-19, it was reported on Thursday.

USFDA has approved hydroxychloroquine sulfate tablets for the treatment of malaria, lupus erythematosus and rheumatoid arthritis. The product is not presently approved for use in the treatment of COVID-19, although it is listed by the World Health Organization as a drug under investigation for use against COVID-19.

The company expects to be in a position to start providing the product by mid-April. It will be able to increase manufacturing to provide 50 million tablets to potentially treat a total of more than 1.5 million patients. This medication for coronavirus related treatment is pending additional FDA and other regulatory body guidance.